Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect

Guo, Haiyan; Sun, Shuai; Yang, Zhenhua; Tang, Xing

doi:10.1016/j.jconrel.2015.04.016

Cited by 15 publications

(4 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Также показано, что этот препарат эффективно подавляет репликацию LASV in vitro, но не влияет на снижение виремии in vivo при инфицировании химерных мышей линии Ifnar-/-B6 C57BL/6 [25]. Есть данные, что накопление препарата в эритроцитах вызывает гемолиз [38], что приводит к развитию анемии и нарушению функции почек [70]. Описан необычный дерматологический побочный эффект рибавирина -угревидные высыпания [39].…”

Section: лечениеunclassified

“…Известно, что рибавирин эффективен, если его прием начат в дебюте болезни [56]. Но важно отметить, что описаны побочные действия препарата -это развитие анемии и нарушение функции почек [38,70]. Зарегистрированные вакцины для профилактики ЛЛ отсутствуют [46], поэтому актуальны подходящие методы лечения, снижающие токсичность рибовирина.…”

unclassified

See 1 more Smart Citation

Lassa fever. Part 2. Laboratory diagnostics, treatment, development of medications

Казачинская

Aripov

Ivanova

et al. 2022

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

Abstract. Globalization and high-speed means of transportation contribute to the spread of infections dangerous to humans. Airborne pathogens have pandemic potential as currently shown in case of the novel coronavirus SARS-CoV-2. Natural focal Lassa fever (LF) common in West African countries, in 35 cases was registered in non-endemic geographical areas because any person infected with Lassa virus (LASV) is a long-term source of infection (up to two months). Cases of person-to-person infection in endemic territories are described. In Germany, the facts of secondary virus transmission from patients to doctors have been recorded during the examination and blood collection from an apparently healthy person as well as during the autopsy of a deceased subjects due to severe LF course.Nonspecific malaise symptoms in LF are also characteristic of numerous other diseases common on the African continent, e.g., malaria and typhoid fever or viral infections such as yellow fever, Chikungunya, dengue and Zika, monkey pox and Ebola virus disease. In this regard, there may be similar dermatological manifestations. Timely detection of cases and differential diagnosis are crucial to ensure safe patient care and use of affordable antiviral therapy for LL provided by the drug ribavirin.research methods for studying LASV use polymerase chain reaction (PCR) for detecting viral RNA, electron microscopy, isolation of infectious virus cultured sensitive cells, indirect immunofluorescence reaction, enzyme immunoassay (ELISA) and immunochromatographic assays for the detection of antibodies and /or antigen as well as immunoblotting. Currently, test kits based on molecular and genetic methods are mainly used for LF laboratory diagnostics.Since the 1980s, ribavirin has been used to treat patients with LF. The serum accumulation of the drug in large quantities causes hemolysis, development of anemia and impaired renal function. In this regard, treatment options are being considered with decline in its concentration due to combined use with other antiviral drugs. A search for new therapeutic agents capable of inhibiting viral replication at disease early stage has been in progress due to lack of any approved vaccines.

show abstract

Section: лечениеunclassified

unclassified

Lassa fever. Part 2. Laboratory diagnostics, treatment, development of medications

Казачинская

Aripov

Ivanova

et al. 2022

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

show abstract

“…Advanced DDS improved the pharmacokinetic profile and stability of drugs, tissue damages on extravasation and drug targeting of the affect sites (Table 3(Tab. 3); References in Table 3: Liu et al, 2006[41]; Harris and Chess, 2003[26]; Veronese and Pasut, 2005[62]; Milla et al, 2012[45]; Guo et al, 2015[25]; Sánchez et al, 2003[54]; Sheffield, 2001[57]; Hashim et al, 2010[27]; Gaillard et al, 2014[18]; Gunaseelan et al, 2010[24]). Advanced DDS comprising liposomes and lipid based formulations are designed in such a way that more stabilized PEG drug complex is formed by linking PEG with interferons (Allen and Cullis, 2004[1]).…”

Section: Pharmaceutical Interventions For the Improvement Of Anti-hcvmentioning

confidence: 99%

Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs

Saleem¹,

Akhtar

Mushtaq³

et al. 2016

EXCLI Journal; 15:Doc578; ISSN 1611-2156

View full text Add to dashboard Cite

“…Some of the functional groups play a key role in drug efficacy and cannot be modified. Thus, it is important to optimize the attachment strategy for anticancer drugs on drug delivery systems. , …”

Section: Introductionmentioning

confidence: 99%

Comparison of Two Approaches for the Attachment of a Drug to Gold Nanoparticles and Their Anticancer Activities

Feng

Chen

et al. 2016

Mol. Pharmaceutics

View full text Add to dashboard Cite

Drug attachment is important in drug delivery for cancer chemotherapy. The elucidation of the release mechanism and biological behavior of a drug is essential for the design of delivery systems. Here, we used a hydrazone bond or an amide bond to attach an anticancer drug, doxorubicin (Dox), to gold nanoparticles (GNPs) and compared the effects of the chemical bond on the anticancer activities of the resulting Dox-GNPs. The drug release efficiency, cytotoxicity, subcellular distribution, and cell apoptosis of hydrazone-linked HDox-GNPs and amide-linked SDox-GNPs were evaluated in several cancer cells. HDox-GNPs exhibited greater potency for drug delivery via triggered release comediated by acidic pH and glutathione (GSH) than SDox-GNPs triggered by GSH alone. Dox released from HDox-GNPs was released in lysosomes and exerted its drug activity by entering the nuclei. Dox from SDox-GNPs was mainly localized in lysosomes, significantly reducing its efficacy against cancer cells. In addition, in vivo studies in tumor-bearing mice demonstrated that HDox-GNPs and SDox-GNPs both accumulate in tumor tissue. However, only HDox-GNPs enhanced inhibition of subcutaneous tumor growth. This study demonstrates that HDox-GNPs display significant advantages in drug release and antitumor efficacy.

show abstract

Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect

Cited by 15 publications

References 114 publications

Lassa fever. Part 2. Laboratory diagnostics, treatment, development of medications

Lassa fever. Part 2. Laboratory diagnostics, treatment, development of medications

Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs

Comparison of Two Approaches for the Attachment of a Drug to Gold Nanoparticles and Their Anticancer Activities

Contact Info

Product

Resources

About